Dr. Sandesh Dev and Dr. C. Michael Gibson discuss: Geographic Disparities in Transthyretin Amyloid Cardiomyopathy Prevalence in United States Veterans.
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.
.
Search
Dr. Jim Januzzi and Dr. C. Michael Gibson discuss: Acoramidis Lowers NT-proBNP in a Larger Proportion of ATTRibute-CM Study Participants With Transthyretin Amyloid.
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.
Dr. Kevin Alexander and Dr. C Michael Gibson discuss: Acoramidis Effect on All-Cause Mortality in Patients with p.V142I (V122I) Variant ATTR-CM: Findings From the ATTRibute-CM Study
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.
Dr. Pam Taub and Dr. C. Michael Gibson discuss: Effects of Lifestyle and Medical Therapy on Changes in Coronary Atherosclerosis: Tracking Plaque for Personalized Medicine
Sponsored by Cleerly, Women as One, and International Atherosclerosis Society
Dr. Marc Bonaca and Dr. C Michael Gibson discuss: When is the world ready for Asymptomatic CAD Screening?
Sponsored by Cleerly, Women as One, and International Atherosclerosis Society
Dr. Danielle Belardo and Dr. C. Michael Gisbon discuss: The Target is the Plaque: Stabilization, Regression, and the Role of Imaging and AI in Modern CAD Management
Sponsored by Cleerly, Women as One and International Atherosclerosis Society
Dr. Masri and Dr. C. Michael Gibson discuss: Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis from ATTRibute-CM
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.
Dr. Maros Ferencik and Dr. C. Michael Gibson discuss: Clinical Utility of Atherosclerosis Imaging in Symptomatic Patients: Lessons Learned from CCTA
Sponsored by Cleerly, Women as One, and International Atherosclerosis Society